Jump to content

Methylenedioxyallylamphetamine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 17:43, 7 July 2015 (Chembox: rm/replace deprecated params. Fix unknown parameters (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Methylenedioxyallylamphetamine
Names
IUPAC name
N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]prop-2-en-1-amine
Identifiers
3D model (JSmol)
ChemSpider
  • InChI=1S/C13H17NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h3-5,8,10,14H,1,6-7,9H2,2H3 ☒N
    Key: BMKCDDFQEGYEJC-UHFFFAOYSA-N ☒N
  • InChI=1/C13H17NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h3-5,8,10,14H,1,6-7,9H2,2H3
    Key: BMKCDDFQEGYEJC-UHFFFAOYAO
  • C1=C2C(=CC=C1CC(C)NCC=C)OCO2
Properties
C13H17NO2
Molar mass 219.283 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

MDAL or 3,4-methylenedioxy-N-allylamphetamine is a lesser-known psychedelic drug. It is also the N-allyl isomer of MDA. MDAL was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines I Have Known And Loved), the minimum dosage is listed as 180 mg, and the duration unknown. MDAL produces few to no effects on its own, but may enhance the effects of LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDAL.

See also

Template:PiHKAL